This podcast has been organised and funded by argenx.
Disclosures:
Querol received research grants from Instituto de Salud Carlos III – Ministry of Economy and Innovation (Spain), CIBERER, Fundació La Marató, GBS-CIDP Foundation International and argenx.
Querol received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi-Genzyme, Annexon, Alnylam, argenx, Dianthus, Biocryst, Montis, LFB, Avilar Therapeutics, Lycia Therapeutics, Nuvig Therapeutics and Takeda.
Querol serves at Clinical Trial Steering Committees for Sanofi Genzyme, argenx and Takeda and is Principal Investigator for UCB’s CIDP01 trial and Sanofi’s Mobilize and Vitalize trials.
In this EMJ podcast, Luis Querol and moderator Yolande Chalmers explore the role of complement in innate immunity, discussing how its dysregulation drives pathophysiological effects, with a focus on the involvement of complement in autoimmune neuromuscular disorders.
Topics covered:
- The role of the complement system in the three key pathways, lectin, classical and alternative
- Consequences of the complement system’s dysregulation
- How understanding of complement may enable identification of therapeutic targets
Moderator:
Yolande Chalmers1
Speaker:
Luis Querol2
1. EMJ, London, UK
2. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
MED-EU-a117-2500003 | Dec 2025
